ASCO Publishes Abstract on Phase I Data for Alnylam Liver Cancer Drug

Notably, the abstract indicates that one patient in the study died from liver failure following treatment, an adverse event that "was deemed possibly related to" the drug.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.